Krabbe Disease
https://link.springer.com/article/10.1186/s13073-026-01620-2
Krabbe disease (KD) is a rare inherited neurological disorder caused by mutations in the GALC gene. These mutations prevent the body from producing enough GALC enzyme, leading to the accumulation of a toxic substance called psychosine. As psychosine builds up, it damages myelin, causing severe neurological decline, and loss of motor function. Current treatments can slow disease progression but do not correct the underlying genetic defect. In this study, researchers tested a gene-editing technology called adenine base editing (ABE) in a mouse model of Krabbe disease. Unlike traditional CRISPR approaches that cut DNA, base editors precisely change a single DNA letter, potentially reducing unwanted side effects. The researchers identified an editor called ABE8e as the most effective and delivered it to newborn mice using an adeno-associated virus (AAV9). Although only a small percentage of cells were genetically corrected, the treatment restored GALC enzyme activity, reduced toxic psychosine levels, improved myelin preservation, and protected nerve fibres. Brain imaging and microscopic analyses confirmed healthier brain tissue in treated animals. These biological improvements translated into better motor performance, increased body weight, and longer survival compared with untreated mice. Importantly, the study showed that even low levels of gene correction can produce meaningful clinical benefits, a finding consistent with previous gene-editing studies in other genetic diseases. The treatment also appeared safe, with no evidence of major adverse effects. While the benefits were partial and further improvements in gene delivery are needed, this work provides strong proof-of-concept that base editing could become a promising future treatment for Krabbe disease and other inherited disorders caused by single-letter DNA mutations.